Information Provided By:
Fly News Breaks for December 23, 2019
RHHBY, SRPT
Dec 23, 2019 | 11:46 EDT
Piper Jaffray analyst Danielle Brill thinks Sarepta's (SRPT) deal with Roche (RHHBY) for ex-U.S. rights to their microdystrophin gene therapy, SRP-9001, is "highly validating" for the program. The analyst believes the large deal signifies safety remains clean in the ongoing Study-102, manufacturing is on-track, and latest efficacy data look good. Brill reiterates an Overweight rating on Sarepta's shares, with a $210 price target.
News For SRPT;RHHBY From the Last 2 Days
RHHBY
RHHBY
RHHBY
Apr 24, 2024 | 06:30 EDT
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.